A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Background: Currently, the accepted standard management of limited-stage small cell lung cancer (SCLC) is concurrent chemoradiotherapy (CCRT), but the frequency of radiotherapy is controversial. Therefore, this meta-analysis, which compared the efficacy and toxicity between twice-daily (BID) and onc...

Full description

Bibliographic Details
Main Authors: Qian Wu, Yiting Xiong, Shujuan Zhang, Xinling Chen, Fengming Yi, Yiping Wei, Wenxiong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
twice-daily
once-daily
concurrent chemoradiotherapy
limited-stage small cell lung cancer
meta-analysis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01460/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01460/full

Similar Items